Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics Inc. has announced the extension of its phase I/II clinical trial for its drug PPMX-T003, targeting the rare aggressive NK-cell leukemia, until March 2026 due to challenges in subject registration. The company is analyzing the potential impact of this extension on its financial results for the current and following fiscal years.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.